The sixth Annual Meeting of the Society of Hematologic Oncology (SOHO 2018) took place on September 12–15, 2018, in Houston, TX.

Highlights from this year's SOHO Annual Meeting include clinical updates on leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas and other related malignancies.

SOHO 2018

12–15 September 2018 | Houston, TX

SOHO 2018

12–15 September 2018 | Houston, TX

The sixth Annual Meeting of the Society of Hematologic Oncology (SOHO 2018) took place on September 12–15, 2018, in Houston, TX.

Highlights from this year's SOHO Annual Meeting include clinical updates on leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas and other related malignancies.

Current landscape and future directions for lower-risk MDS treatment 1:39
Current landscape and future directions for lower-risk MDS treatment
David Steensma • 12 Sep 2018
Fourth generation TKIs for CML: asciminib 1:32
Fourth generation TKIs for CML: asciminib
Michael Mauro • 12 Sep 2018
The unmet needs in low-risk MDS 0:55
The unmet needs in low-risk MDS
David Steensma • 12 Sep 2018
Successful TFR in DASFREE: dasatinib for R/R CML 2:20
Successful TFR in DASFREE: dasatinib for R/R CML
Michael Mauro • 12 Sep 2018
Promising approaches and clinical trials in MDS 1:56
Promising approaches and clinical trials in MDS
David Steensma • 12 Sep 2018
Benefits of second generation TKIs for CML in the frontline 1:46
Benefits of second generation TKIs for CML in the frontline
Giuseppe Saglio • 12 Sep 2018
Asciminib plus traditonal TKIs for chronic phase CML 3:08
Asciminib plus traditonal TKIs for chronic phase CML
Giuseppe Saglio • 12 Sep 2018
Resistance/intolerance to second generation TKIs in CML: what to do next? 2:15
Resistance/intolerance to second generation TKIs in CML: what to do next?
Giuseppe Saglio • 12 Sep 2018
Midostaurin and quizartinib: improving survival and day-to-day life in AML 1:36
Midostaurin and quizartinib: improving survival and day-to-day life in AML
Alexander Perl • 12 Sep 2018
Current research in elderly, untreated AML: venetoclax combinations 3:05
Current research in elderly, untreated AML: venetoclax combinations
Marina Konopleva • 12 Sep 2018
Predictors for TFR in CML: response duration, secondary treatment & frontline TKI choice 3:18
Predictors for TFR in CML: response duration, secondary treatment & frontline TKI choice
Timothy Hughes • 12 Sep 2018
Genetic biomarkers of response to venetoclax in AML 2:57
Genetic biomarkers of response to venetoclax in AML
Marina Konopleva • 12 Sep 2018
CAR T-cells in CLL: the current landscape 3:39
CAR T-cells in CLL: the current landscape
William Wierda • 12 Sep 2018
Update on ENESTop: TFR in CML after discontinuing nilotinib 2:36
Update on ENESTop: TFR in CML after discontinuing nilotinib
Timothy Hughes • 12 Sep 2018
Venetoclax combinations effective in elderly AML 3:20
Venetoclax combinations effective in elderly AML
Marina Konopleva • 12 Sep 2018
Allogeneic CD123-targeting CAR T-cell for AML: risks and potential 3:33
Allogeneic CD123-targeting CAR T-cell for AML: risks and potential
Marina Konopleva • 12 Sep 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals